Turinabol (17-alpha-acetoxy-11beta-hydroxyandrostan-3-one) is a synthetic steroidal anabolic-androgenic steroid (AAS). Turinabol was first synthesized by Dr. John B. Adams at the University of North Carolina in 1957. He named it after his wife, Turina. It is closely related to nandrolone (19-nortestosterone), methandrostenolone (17-methyl-19-nor-testosterone), and oxymetholone (17-alpha-methyltestosterone).
The chemical structure of turinabol is similar to that of testosterone, although its 17 alpha position is substituted with acetate instead of hydrogen. Turinabol is a potent AAS that is structurally similar to methyltrienolone (MTT) and methyltestosterone (MST). MTT is a 19-norsteroid that is closely related to norethandrolone (NOR) and norbolethone (NOBE). NOR is a 19-nor-anabolic steroid that is closely related to mesterolone (MET). In addition, it is closely related to stanozolol (STAN) and epiandrosterone (EPI). EPI is a naturally occurring C21 steroid hormone produced by the adrenal gland.
Turinabol is a powerful muscle builder and performance enhancer. It is commonly used in bodybuilding competitions and professional sports. It is also used for increasing lean muscle mass and promoting recovery. Turinabol is often used in conjunction with other steroids.
Turinabol’s effects last approximately three days. Its duration of action is longer than that of many other AAS. However, it does not have the same long term side effects as some other AAS. Because of this, it is considered to be a safer drug.
Turinabol has been banned in several countries due to its potential to cause liver damage. It is banned in Germany, Italy, Switzerland, Austria, France, Belgium, and Spain. It is also banned in the United Kingdom and Australia.
Turinabol comes in both oral and injectable forms. Oral doses range from 50mg to 500mg per day. An injectable dose is 10mg/ml.